Bristol-Myers Squibb: Neoplasm Metastasis trials

The registry lists 22 Neoplasm Metastasis studies with Bristol-Myers Squibb as lead sponsor. 1 are open to participants now and 5 have results posted.

Phase 1 12Phase 2 11Phase 3 4No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsRecruitingNCT04094610Phase 1/2
• A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose CombinationsActive, not recruitingNCT06101134Phase 2Results posted
• Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C MutationActive, not recruitingNCT04685135Phase 3Results posted
• A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid TumorsTerminatedNCT00886782Phase 1/2Results posted
• Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate CancerCompletedNCT00323882Phase 1/2Results posted
• Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast CancerTerminatedNCT00281528Phase 2Results posted
• Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)Active, not recruitingNCT05853575Phase 2
• Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C MutationApproved for marketingNCT05162443
• Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)TerminatedNCT04975256Phase 1
• Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)CompletedNCT04330664Phase 1
• Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in METActive, not recruitingNCT03993873Phase 1
• Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1Active, not recruitingNCT03785249Phase 1/2
• Safety and PK Study of CC-90003 in Relapsed/Refractory Solid TumorsTerminatedNCT02313012Phase 1
• Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.CompletedNCT01353625Phase 1
• Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid TumorsTerminatedNCT00908024Phase 1/2
• MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid TumorsCompletedNCT00207103Phase 1
• A Research Study for Patients With Metastatic Renal Cell CarcinomaCompletedNCT00106613Phase 2
• Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.CompletedNCT00057616Phase 3
• Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant MelanomaCompletedNCT00055562Phase 2/3
• Study of ABI-007 and Taxol in Patients With Metastatic Breast CancerCompletedNCT00046527Phase 3
• ABI-007 in Taxol Resistant Patients With Metastatic Breast CancerCompletedNCT00046514Phase 2
• A Trial of ABI-007 in Patients With Advanced Non-Hematologic MalignanciesCompletedNCT00046423Phase 1